355 related articles for article (PubMed ID: 25634099)
1. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
Feng D; Leong M; Li T; Chen L; Li T
World J Surg Oncol; 2015 Jan; 13():11. PubMed ID: 25634099
[TBL] [Abstract][Full Text] [Related]
2. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
3. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
4. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma.
Honma Y; Yamada Y; Terazawa T; Takashima A; Iwasa S; Kato K; Hamaguchi T; Shimada Y; Ohashi M; Morita S; Fukagawa T; Machida N; Katai H
Surg Today; 2016 Sep; 46(9):1076-82. PubMed ID: 26563224
[TBL] [Abstract][Full Text] [Related]
6. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
7. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
[TBL] [Abstract][Full Text] [Related]
8. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Kang YK; Yook JH; Park YK; Lee JS; Kim YW; Kim JY; Ryu MH; Rha SY; Chung IJ; Kim IH; Oh SC; Park YS; Son T; Jung MR; Heo MH; Kim HK; Park C; Yoo CH; Choi JH; Zang DY; Jang YJ; Sul JY; Kim JG; Kim BS; Beom SH; Cho SH; Ryu SW; Kook MC; Ryoo BY; Kim HK; Yoo MW; Lee NS; Lee SH; Kim G; Lee Y; Lee JH; Noh SH
J Clin Oncol; 2021 Sep; 39(26):2903-2913. PubMed ID: 34133211
[TBL] [Abstract][Full Text] [Related]
9. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
[TBL] [Abstract][Full Text] [Related]
10. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
[TBL] [Abstract][Full Text] [Related]
11. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer.
Yu YJ; Sun WJ; Lu MD; Wang FH; Qi DS; Zhang Y; Li PH; Huang H; You T; Zheng ZQ
World J Gastroenterol; 2014 Dec; 20(48):18413-9. PubMed ID: 25561810
[TBL] [Abstract][Full Text] [Related]
13. [A Successful Treatment for Stage III c Gastric Cancer with Low Cardiac Function Using S-1 plus Oxaliplatin(SOX)as a Neoadjuvant Chemotherapy].
Terashima T; Kawamoto S; Maekawa K; Kuroki N
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1892-1894. PubMed ID: 29394811
[TBL] [Abstract][Full Text] [Related]
14. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.
Hosoda K; Azuma M; Katada C; Moriya H; Mieno H; Ishido K; Ema A; Ushiku H; Wada T; Washio M; Watanabe A; Higuchi K; Tanabe S; Koizumi W; Watanabe M; Yamashita K
Gastric Cancer; 2019 May; 22(3):598-606. PubMed ID: 30284080
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.
Satake H; Kondo M; Mizumoto M; Kotake T; Okita Y; Ogata T; Hatachi Y; Yasui H; Miki A; Imai Y; Ichikawa C; Murotani K; Kotaka M; Kato T; Kaihara S; Tsuji A
Anticancer Res; 2017 Jul; 37(7):3703-3710. PubMed ID: 28668863
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer clinical T4 or N2-3.
Serizawa A; Kuramochi H; Taniguchi K; Ota M; Katagiri S; Yamada T; Kotake S; Ito S; Suzuki K; Yamamoto M
Med Oncol; 2021 Jul; 38(9):98. PubMed ID: 34302539
[TBL] [Abstract][Full Text] [Related]
18. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Advanced Gastric Cancer with a Pathological Complete Response after Neoadjuvant Chemotherapy(S-1/Oxaliplatin)].
Suematsu Y; Yamagishi S; Saito H; Takahashi M; Nakayama M; Fukabori M; Morita A; Wakabayashi K; Itoh Y
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2225-2227. PubMed ID: 28133277
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Stage IV Gastric Cancer Which Showed Pathological Complete Response after Neo-Adjuvant Chemotherapy].
Nakao E; Ozawa R; Takii M; Kaibe N; Kurahashi Y; Oshima T; Niwa H; Kikuchi S; Sasako M; Shinohara H
Gan To Kagaku Ryoho; 2018 Apr; 45(4):667-669. PubMed ID: 29650829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
